TIDES Asia 2021 will take place on March 2 – 5 as a virtual webinar series presented in Japan Standard Time (JST). The Virtual Scientific Forum is free to attend and consists of 4 world-renowned keynote speakers and several cutting-edge technology company and CMO speakers who will present some of the latest R&D and CMC/manufacturing developments in the field. Join our presentations on Day Two, Wednesday, March 3rd:
10:00am – 11:00am: Dr. Jyothi Thundimadathil, Associate Director, Bachem Americas, will present “Microspheres and Nanoparticles for Peptide Delivery”
11:00am – 12:00pm: Dr. Wolfgang Seufert, Director of Production, Bachem AG will present “Solubility-directed Development of Trileucine Process”
We kindly invite you to check the TIDES Asia Resources Center for additional Bachem content (e.g. our poster “A New Turn on Peptide Purification” or the video “Oligonucleotides@Bachem”). We look forward to e-connect with you at TIDES Asia 2021!
In vitro diagnostics are increasingly important around the world as a first defense against the spread of many diseases. They are defined as reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. In vitro diagnostics have become essential and critical tools for medicine practice for diagnostics in order to rapidly detect with accuracy diseases and changes in drug resistance. Peptide-based in vitro diagnostics are used in particular for detection of infectious diseases, cardiac diseases, cancer and immune disorders.
The year 2020 brought positive developments in the form of approved drug applications for peptides. The U.S. Food and Drug Administration (FDA) approved Rhythm Pharmaceuticals’ Imcivree (setmelanotide), a novel peptide-based drug for the treatment of obesity and the control of hunger associated with pro-opiomelanocortin deficiency. In Europe, the European Medicines Agency (EMA) granted conditional approval to MYR Pharmaceuticals’ Hepcludex (bulevirtide) for the treatment of Hepatitis D virus (HDV) infection. In addition, drugs with leuprolide, octreotide and vasopressin as active pharmaceutical ingredients were among the approved Abbreviated New Drug Applications (ANDA) and 505(b) applications.
MEET BACHEM: PHILIPPE THERON, SALES MANAGER CUSTOM SYNTHESIS
This month the spotlight is on Philippe Théron, Sales Manager Custom Synthesis in the Sales Research Chemicals Department at Bachem AG. Learn about Philippe’s role at Bachem and what he likes to do in his free time.
This month's highlights include news about the combination of VEGFR inhibitor drugs with angiotensin-(1,7) to overcome treatment resistance and to improve survival in mice with kidney cancer, about the discovery of remarkable molecular properties of an antimicrobial peptide from Australian todlet skin, about the development from Silo Pharma of a novel peptide-guided delivery system for multiple sclerosis treatments, and about immune cell proteins that act as an anti-inflammatory drug to reduce blood clotting in people with Sickle Cell Disease.
All information is compiled to the best of our knowledge. We cannot be made liable for any possible errors or misprints. Some products may be restricted in certain countries.
